RESUMO
Liver transplantation (LT) for cholangiocarcinoma (CCA) remains limited to a small number of centers. Although the role of neoadjuvant therapy (NAT) has been explored over time, an in-depth analysis of NAT strategies remains limited. Furthermore, controversy exists regarding acceptable tumor size during patient selection for LT. This study explores the impact of era, tumor size, and NAT strategy on LT outcomes for CCA. We conducted a retrospective review of 53 patients with CCA treated with LT from 1985 to 2019; 19 hilar CCA (hCCA) and 30 intrahepatic CCA (iCCA) were included. The relative contributions of varying NAT (neoadjuvant chemotherapy [NAC], neoadjuvant local therapy [NALT], and combined NAC and NALT [NACLT]) as well as the implication of tumor size and era were analyzed. The primary endpoint was overall survival (OS). Compared with the old era (1985-2007), 5-year OS in patients who underwent LT in the recent era (2008-2019) showed a superior trend. The 5-year OS from initial treatment in patients receiving NACLT for hCCA and iCCA were 88% and 100% versus 9% and 41% in patients without it, respectively (P = 0.01 for hCCA; P = 0.02 for iCCA), whereas NAC or NALT alone did not show significant differences in OS versus no NAT (P > 0.05). Although 33 patients had large-size tumors (hCCA ≥ 30 mm, n = 12, or iCCA ≥ 50 mm, n = 21), tumor size had no impact on survival outcomes. Outcomes of LT for CCA seem to have improved over time. Multimodal NAT is associated with improved survival in LT for both iCCA and hCCA regardless of tumor size.
Assuntos
Neoplasias dos Ductos Biliares , Colangiocarcinoma , Transplante de Fígado , Neoplasias dos Ductos Biliares/cirurgia , Ductos Biliares Intra-Hepáticos/patologia , Colangiocarcinoma/cirurgia , Humanos , Transplante de Fígado/efeitos adversos , Terapia Neoadjuvante , Resultado do TratamentoRESUMO
AIMS: This clinical audit aimed to review the Faster Cancer Tract pathway in Northland patients with gynaecological cancers to evaluate whether there has been an improvement since the previous audit in 2014-2015. METHODS: There were 46 patients who were discussed at the gynaecological oncology multidisciplinary meeting between January 2016 and December 2016 with confirmed gynaecological malignancy. Information regarding the time taken for various investigations, referrals, decisions and treatment to be completed for each patient was obtained from clinical records and compared against the Ministry of Health faster cancer treatment targets, standards of service provision and data from the previous audit. RESULTS: Overall, 85% of patients met the target of having their first treatment within 31 days of a decision being made for treatment. 45% of patients met the target of having their first treatment within 62 days of initial referral for suspected cancer. This reflects an overall improvement in service provision from the previous audit period, which showed targets being met in 73% and 39% of cases respectively. CONCLUSION: There has been an overall improvement in cancer care service provision for Northland patients since the previous audit, however it still falls short of the national FCT targets.